1283719-69-6 Usage
Uses
Used in Medicinal Chemistry:
Tricyclo[3.3.1.13,7]decan-1-ethanesulfonaMide is used as a potential building block for the synthesis of new drug candidates due to its diverse and complex structure. Its unique tricyclic framework provides a foundation for the development of innovative pharmaceuticals with a broad range of biological activities.
Used in Pharmaceutical Research:
Tricyclo[3.3.1.13,7]decan-1-ethanesulfonaMide is employed as a research tool in the study of novel drug design and discovery. Its unique structure and potential for exhibiting various biological activities make it an attractive candidate for exploring new therapeutic agents and understanding their mechanisms of action.
Used in Drug Development:
Tricyclo[3.3.1.13,7]decan-1-ethanesulfonaMide is utilized in the development of new pharmaceuticals with potential applications in various therapeutic areas. Its diverse structure allows for the exploration of different chemical modifications and the synthesis of drug candidates with improved pharmacological properties, such as enhanced efficacy, selectivity, and reduced side effects.
Used in Drug Discovery:
Tricyclo[3.3.1.13,7]decan-1-ethanesulfonaMide is used in the discovery of new drugs with potential therapeutic benefits. Its unique tricyclic structure and the ability to exhibit a wide range of biological activities make it an ideal starting point for the identification and optimization of novel drug candidates with potential applications in various medical fields.
Check Digit Verification of cas no
The CAS Registry Mumber 1283719-69-6 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,8,3,7,1 and 9 respectively; the second part has 2 digits, 6 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1283719-69:
(9*1)+(8*2)+(7*8)+(6*3)+(5*7)+(4*1)+(3*9)+(2*6)+(1*9)=186
186 % 10 = 6
So 1283719-69-6 is a valid CAS Registry Number.
1283719-69-6Relevant academic research and scientific papers
Lipophilic isosteres of a π-π Stacking interaction: New inhibitors of the Bcl-2-Bak protein-protein interaction
Yusuff, Naeem,Dore, Michael,Joud, Carol,Visser, Michael,Springer, Clayton,Xie, Xiaoling,Herlihy, Kara,Porter, Dale,Toure, B. Barry
, p. 579 - 583 (2012/09/08)
The discovery of new Bcl-2 protein-protein interaction antagonists is described. We replaced the northern fragment of ABT737 (π-π stacking interactions) with structurally simplified hydrophobic cage structures with much reduced conformational flexibility and rotational freedom. The binding mode of the compounds was elucidated by X-ray crystallography, and the compounds showed excellent oral bioavailability and clearance in rat PK studies.
